Oric Pharmaceuticals Price Target Cut to $14.00/Share From $17.00 by Wedbush

What happened

Wedbush cut its price target on Oric Pharmaceuticals to $14.00 per share from $17.00 while keeping an Outperform rating on the stock, according to ratings actions reported by Benzinga.

Confirmed

Global impact / market context

A lower price target means Wedbush expects less upside than before, though Outperform still signals it sees the stock beating the market. Investors may treat the cut as a modest reduction in expected return rather than a negative call on the company.

Analyst inference

Analyst price targets are estimates, not guarantees, and a target cut with an unchanged Outperform rating suggests the broker trimmed its expectations rather than changed its view. The article gives no reason for the cut, so the driver is unknown.

Analyst inference

What to watch

1. Wedbush maintained its Outperform rating on Oric Pharmaceuticals while lowering the price target to $14.00 from $17.00. Confirmed
2. Watch whether other analysts follow with their own target changes, which would show whether the revision reflects a broader shift in expectations. Proposed
3. Watch for company updates on spending, cash available, or trial progress, since these could explain whether the lower target reflects slower expected progress. Analyst inference

Evidence

• Original source link unavailable